H.C. Wainwright lowered the firm’s price target on Context Therapeutics (CNTX) to $4 from $5 and keeps a Buy rating on the shares following the Q2 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX: